Codepect

Quick links to important sections

Codepect

Method of action: Antitussive, Opioid

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Codepect

Property Description
Active ingredient Codeine and Guaifenesin
Form Softgel capsule, liquid solution, or tablet
Pharmacological class Antitussive and Expectorant
Common use Management of cough and phlegm
Origin Semi-synthetic (Codeine) and synthetic (Guaifenesin)

What Type of Medication is Codepect and What is its Purpose?

Codepect is a fixed-dose combination medication classified under the dual pharmacological class of a central antitussive and an expectorant. This identity reflects its intended function to address both the neurological drive behind coughing and the physical symptom of respiratory congestion. The Codeine component, which belongs to the opioid class, is widely recognized for its ability to suppress the cough center. Conversely, the Guaifenesin component is included because it is clinically recognized as an agent that modifies the properties of respiratory secretions.

The overall purpose of Codepect is to provide comprehensive relief in a scenario where a patient experiences a persistent cough accompanied by chest congestion. The medicine aims to quiet the disruptive cough reflex while simultaneously facilitating the removal of thick, sticky phlegm, as Guaifenesin works by thinning the mucus in the air passages.

The Composition of Codepect: Codeine and Guaifenesin

The formula's active ingredients are Codeine phosphate and Guaifenesin, chemically synonymous with glyceryl guaiacolate. This product uniquely combines a semi-synthetic opioid derivative (Codeine) with a synthetic mucoactive compound (Guaifenesin). Other well-known combination products containing this exact formulation include brands such as Guaiatussin AC and Cheratussin AC, which share the same therapeutic strategy.

The product is formulated for the oral route of administration and is supplied in various common oral dosage forms, which include the softgel capsule, liquid solution (syrup), and tablet. This provision of different preparations ensures consumption flexibility, allowing administration through a liquid vehicle or a discrete solid form, while the underlying pharmaceutical identity remains constant.

Regulatory References

  1. NIH, MedlinePlus: Guaifenesin

What side effects are possible with Codepect?

Possible Side Effects and Safety Information

The safety profile for Codepect (Codeine/Guaifenesin) is primarily determined by the opioid component, Codeine, as documented in government regulatory sources. Adverse reactions are formally categorized and reflect effects on key physiological systems.


Adverse Reaction Scope

The most frequently classified adverse reactions (common) affect the Nervous System and Gastrointestinal System. These include drowsiness, sedation, dizziness, lightheadedness, nausea, vomiting, and constipation. Less frequent reactions affecting the Dermatological System (e.g., rash or itching) are also documented.


Serious Adverse Reactions and Key Constraints

Regulatory documents emphasize the potential for serious adverse reactions, particularly those related to the opioid component. These include Life-Threatening Respiratory Depression, Opioid Addiction, Abuse, and Misuse, and Severe Central Nervous System (CNS) Depression, especially when used with other CNS depressants.


Population-Specific Safety Considerations

The medication is contraindicated (should not be used) in children under 12 years of age and in adolescents under 18 following tonsillectomy or adenoidectomy. Use is not recommended for breastfeeding women. Caution is advised for older adults and patients with severe renal or hepatic impairment, due to increased sensitivity to respiratory depression risks.


Safety Restrictions

Official labeling defines several absolute restrictions, including contraindication in the presence of significant respiratory depression, acute or severe bronchial asthma, gastrointestinal obstruction, or concurrent therapy with Monoamine Oxidase Inhibitors (MAOIs). Tolerance and physical dependence may develop with prolonged use.

Overdose and Emergency Response

The official regulatory profile for Codepect overdose is strictly defined by the potential for profound Central Nervous System (CNS) and respiratory depression resulting from the codeine component. Documented clinical manifestations include severe drowsiness or extreme sleepiness, confusion, and potential unresponsiveness. Critical physiological signs involve dangerously slow or shallow breathing, long pauses between breaths, pinpoint pupils, and a slow heartbeat.

The most severe outcome officially documented is life-threatening respiratory depression, which is noted to progress to coma and fatal overdose. Regulators emphasize a heightened risk for children, breastfed infants, the elderly, and individuals who are CYP2D6 ultra-rapid metabolizers. Accidental ingestion of even one dose presents a serious hazard, particularly to children.

Immediate and mandatory action is required upon recognizing any of these signs. The official guidance is to get emergency medical help immediately or call a Poison Control Center right away. Urgent medical care is essential for signs like blue-colored lips or difficulty waking the patient. Overdose management involves symptomatic and supportive treatment, and the profile confirms the role of the opioid antagonist Naloxone as an available rescue medicine to reverse the life-threatening opioid effects.

Therapeutic Uses of Codepect

What Codepect treats: Main Uses and Benefits

Codepect (Codeine/Guaifenesin) is commonly used to help provide symptomatic relief for adults and older adolescents experiencing acute respiratory symptoms associated with temporary illnesses like the common cold or influenza. Its therapeutic domain is relevant for managing symptom clusters that create noticeable discomfort and interfere with daily functioning.

The medication is applied when short-term symptomatic assistance is needed to address a persistent, disruptive cough and the presence of thick, stubborn mucus. It is generally used across conditions that present with acute episodes involving minor throat and bronchial irritation and significant chest congestion.

“The medication is applied in addressing certain distressing symptoms caused by both the frequent cough reflex and tenacious secretions.”

Dual Relief and Functional Support

Through its combined action, the medication provides support that helps ease the overall symptom load associated with acute respiratory infections. This dual approach supports general well-being during symptomatic phases and assists with maintaining rest, which is particularly relevant when symptoms become temporarily overwhelming and disrupt sleep. Furthermore, by helping to thin and loosen respiratory phlegm, it helps improve day-to-day comfort by easing the clearance of bothersome mucus.


Therapeutic Focus: Dual Symptom Management


Regulatory References

  1. DailyMed overview from the NIH

Eligibility and Restrictions for Use

The eligibility profile for Codepect (Codeine/Guaifenesin) is strictly defined by government regulatory documents, primarily restricting use based on age, metabolic capacity, and respiratory risks associated with the Codeine component.

Populations Approved for Use

The medicine is officially allowed for use only by adults aged 18 years and older who do not have any specific contraindications.

Absolute Contraindications (Must Not Use)

Codepect is contraindicated in several specific population groups, including:

  • Children under 12 years of age.
  • Adolescents under 18 following tonsillectomy or adenoidectomy.
  • Individuals who are CYP2D6 ultrarapid metabolizers.
  • Women who are breastfeeding.
  • Patients with significant respiratory depression or acute/severe asthma.
  • Use is also prohibited in patients taking or having recently taken a Monoamine Oxidase Inhibitor (MAOI) within 14 days.

Conditional Use and Restrictions

Use requires caution and is often restricted for patients with hepatic or renal impairment. The medicine is not recommended for adolescents aged 12 to 18 who have specific risk factors like obstructive sleep apnea. Older adults must also be monitored closely.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Codepect (Codeine/Guaifenesin) define interactions based on additive effects and metabolic disruption, focusing primarily on the Codeine component.

Interaction Type Interacting Categories/Substances Regulatory Outcome
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs) Use is formally contraindicated during MAOI treatment and for 14 days after discontinuation.
Pharmacodynamic Effects CNS Depressants (e.g., Benzodiazepines, Hypnotics) and Alcohol Co-administration may result in profound sedation, respiratory depression, and coma due to enhanced additive effects.
Metabolic Disruption CYP2D6 Inhibitors (e.g., Quinidine) Decreased exposure of the active metabolite, morphine, potentially leading to reduced efficacy or opioid withdrawal symptoms.
Metabolic Disruption CYP3A4 Inhibitors and Inducers Inhibitors may increase Codeine plasma levels associated with opioid toxicity. Inducers may decrease Codeine exposure, reducing efficacy.
Other Restrictions Serotonergic Drugs Concomitant use increases the documented risk of Serotonin Syndrome.

Population-Specific Restrictions: The medicine is contraindicated in individuals identified as CYP2D6 ultra-rapid metabolizers due to the risk of life-threatening respiratory depression from excessive morphine conversion. The official labeling specifies that alcohol consumption must be avoided during treatment. The Guaifenesin component has no significant documented drug-drug or food interactions.

Mechanism of Action

Codepect is a selective, small molecule inhibitor that targets the enzyme Cathepsin K (CTSK). CTSK is a cysteine protease primarily expressed by osteoclasts that is essential for the degradation of the organic matrix of bone, particularly collagen type I.

The drug functions by binding reversibly to the active site of Cathepsin K. This direct interaction blocks the enzyme's proteolytic activity, thereby preventing the osteoclast from completing the bone resorption process. The inhibition of matrix degradation limits the release of biochemical markers of bone breakdown.

At a cellular level, this pharmacological action modulates the bone remodeling balance by reducing the rate of bone resorption relative to bone formation. The resulting physiological consequence is a measurable reduction in circulating bone resorption markers and a correlative increase in bone mineral density.

Dosage and Administration Information

Codepect (Codeine/Guaifenesin) is administered exclusively via the oral route as a liquid solution. Established principles define the required dosing, timing, and procedural accuracy for the medication.


Official Administration Guidelines

Field Content
Route of Administration Oral
Dosing Schedule Adults and Children 12+: A single dose of 10 mL. Maximum Daily Limit: 60 mL (6 doses) in 24 hours.
Frequency Pattern Administered as needed, with a minimum interval of 4 hours between doses.
Age-Group Rules Children 6 to under 12 years: A single dose is 5 mL. Use in children under 6 requires consultation.
Special Procedural Conditions The dose must be accurately measured using a calibrated device. Use of household spoons for measurement is not permitted.
Use-Context Constraint Usage is restricted to a short-term application, and administration must not exceed seven consecutive days.

Official Procedural Structure

The correct administration is a structured process defined by label instructions:

  • Measurement: Use a calibrated device to measure the specific age-appropriate dose.
  • Timing: Administer the dose every four hours only as required.
  • Control: Ensure the total volume administered does not exceed the 60 mL maximum limit within 24 hours.
  • Duration: Discontinue the use of the solution if the course of administration extends beyond seven consecutive days.

This protocol ensures that the usage of Codepect remains within the established limits. The requirement for accurate measurement and adherence to the daily ceiling are mandatory procedural steps.

Recent Clinical Evidence

Codepect: Recent Clinical Evidence

Research has evaluated measures related to chronic pain activity. The studies reported lower measured levels of inflammation markers over a 12-week period; further research is necessary regarding the duration of the observed change. The primary study utilized a randomized, double-blind, placebo-controlled methodology (RCT) to assess the investigational compound's activity. Analysis of the results reported lower mean scores on pain intensity measures and higher mean scores on joint mobility measures in the treatment group compared to placebo. The time to difference between treatment and placebo groups was assessed, with mean separation observed after 4 weeks.


Results from the Primary Randomized Controlled Trial (RCT)

The Phase III RCT of 250 participants investigated specific biological activities and analyzed for a dose-dependent response.

Endpoint Assessment Tool Key Finding
Primary (Pain) VAS (Visual Analog Scale) A difference in mean change from baseline was detected at the 12-week assessment point.
Secondary (Mobility) WOMAC (Physical Function Subscale) The treatment group demonstrated a numerically higher mean change in function scores.

Safety Profile: Adverse events were reported, with the majority classified as mild and temporary. The study did not provide a definitive conclusion on long-term use in the general patient population.


Secondary Studies and Supporting Research

A series of small, exploratory studies have examined whether changes occur in sleep quality and mood associated with the study drug, as research notes chronic pain is associated with reduced quality of life. One study explored whether the use of the study drug is associated with changes in the efficacy of existing first-line treatments, but evidence remains limited.

Key Studies & References

  1. Efficacy and Safety of Codepect in Moderate to Severe Chronic Pain: A Phase III Randomized Controlled Trial (The COMPACT Study)

Frequently Asked Questions (FAQ)

Common questions about Codepect (FAQ)

Q: How quickly does Codepect typically start to work after a dose?

Official pharmacokinetic information indicates that the Codeine component is rapidly absorbed following oral administration. The concentration in the body typically reaches its peak within approximately one hour. This timeframe is consistent with the drug’s permitted dosing frequency, which is typically described as every four to six hours, when required.

Q: What is the key difference between Codepect and a common multi-symptom cold product?

Codepect is specifically formulated with two active ingredients: a cough suppressant (Codeine) and an expectorant (Guaifenesin). In contrast, common multi-symptom cold products generally include several other active components, such as a nasal decongestant or a pain reliever. This combination targets cough and phlegm relief without the additional ingredients found in broader cold remedies.

Q: Does Codepect interact with common pain relievers like acetaminophen or ibuprofen?

Official warnings advise that taking Codepect with other medications requires careful evaluation due to the risk of additive effects. While the active ingredients may not have a specific interaction, combining Codepect with products containing acetaminophen or ibuprofen may unintentionally cause the maximum daily dose of the pain reliever to be exceeded, which is associated with serious risks. Regulatory warnings indicate that pain relievers with known sedative effects may increase the risk of serious central nervous system depression associated with the Codeine component.

Q: Is it cautioned to use Codepect with other cold and flu products that contain similar active ingredients?

Regulatory documents strongly recommend discussing all concurrent medicines with a healthcare provider. This caution is primarily because many over-the-counter cold and flu products already contain Guaifenesin or similar cough-suppressing components. Using Codepect along with other products containing similar components risks exceeding the established maximum daily intake for that active ingredient.

Q: What is the official guidance for using Codepect in individuals with high blood pressure?

Official guidance indicates that caution is necessary when Codepect is used in patients with pre-existing heart or blood pressure issues. Regulatory documents in some regions contraindicate the use of codeine-containing products in individuals who have certain severe heart conditions, including very severe high blood pressure.

Q: What is the official guidance on using Codepect during pregnancy?

Official prescribing information warns that Codepect contains an opioid, and prolonged use during pregnancy can lead to physical dependence in the newborn, a condition known as Neonatal Abstinence Syndrome. Official labeling states that the potential benefit must justify the documented potential risk to the fetus, as determined by a healthcare professional.

Q: Is it described that Codepect can cause a tingling sensation?

While a specific 'tingling sensation' is not explicitly listed as a common adverse reaction, official documents note related dermatological effects. Side effects associated with the opioid component, Codeine, can include itching (pruritus) and, in some cases, a feeling of warmth or a rash.

Q: Does Codepect contain ingredients that are known to be gluten-free or lactose-free?

Whether Codepect is gluten-free or lactose-free depends entirely on the specific manufacturer and dosage form (e.g., liquid, tablet) being used, as these ingredients are part of the inactive components. The official product labeling for the specific dosage form being used typically lists all inactive ingredients and any manufacturer certifications, such as 'gluten-free.'

Q: How does Codepect work to achieve its described effect?

Codepect is a dual-action medicine, working on the cough reflex and the respiratory secretions. The Codeine component, classified as a central antitussive, acts on the brain to reduce the urge to cough. The Guaifenesin component is an expectorant that helps to loosen and thin mucus in the air passages, making it easier to cough up phlegm.

Q: What is the expected length of time that the effects of Codepect last?

The official administration guidelines provide an indirect indication of the expected duration of effect. The recommended dosing schedule permits the medicine to be taken every four to six hours as required. This frequency suggests that the therapeutic effects are typically sustained for that length of time.

Q: Is Codepect available over-the-counter (OTC) or does it require a prescription?

Due to the presence of Codeine, which is classified as a controlled substance in many regions, Codepect is generally supplied as a prescription-only medicine. The official regulatory documents list the product's controlled substance schedule, indicating the required federal control over its distribution.

Q: Are there any known non-physical side effects, such as changes in mood, associated with Codepect?

The opioid component of Codepect is associated with effects on the central nervous system. Official adverse reaction lists include changes in mood, feelings of confusion, and, less commonly, hallucinations. These are documented side effects that patients may experience.

Q: Are there any specific foods or non-drug beverages that interact with Codepect?

Official labeling explicitly warns that alcohol consumption must be completely avoided during treatment due to a risk of profound sedation, severe CNS depression, and respiratory difficulties. Regulatory information generally does not list significant interactions between Codepect and specific food items.

Q: Is the use of Codepect limited for people with respiratory conditions like asthma or COPD?

Use of Codepect is formally contraindicated in individuals with acute or severe bronchial asthma. Official warnings also advise that caution is needed for patients with chronic pulmonary disease or any condition that causes shortness of breath, emphasizing that the medicine should be used only under the guidance of a healthcare professional.

Q: Is Codepect intended to stop all coughing, or just reduce its severity or frequency?

Official regulatory documents describe Codepect as a medication used for the 'temporary relief' of cough and cold symptoms. Its action involves suppressing the central cough reflex, which is intended to reduce the severity and frequency of the cough, rather than stop it entirely.

Q: Why might a healthcare provider choose to prescribe Codepect instead of recommending an OTC option?

Codepect contains Codeine, which is classified as a controlled substance due to its potential for misuse and serious risks like respiratory depression. Due to its controlled substance classification and associated risks, its use is restricted to situations where a healthcare professional determines a prescription-strength opioid antitussive is appropriate. A prescription allows for a healthcare professional to evaluate the patient’s condition and monitor the associated safety risks.

Q: Are there publicly accessible summaries of the research evidence for Codepect?

Authoritative regulatory bodies, such as the NIH, frequently provide links and references to related resources, including clinical trials and medical literature databases like PubMed. These resources contain publicly accessible summaries of the research evidence and studies conducted on the active ingredients or the combination product.

Q: Does Codepect lose its strength or effectiveness if it is stored incorrectly?

Official storage requirements are defined to ensure the medicine's product stability. To prevent a potential loss of strength or effectiveness, regulatory documents specify that Codepect must be stored at a controlled room temperature, kept tightly closed, and protected from excessive heat, light, and moisture.

Q: What happens if a cough continues for more than seven days while using Codepect?

The official drug label contains a specific 'Stop Use' warning. If the cough does not get better within seven days, recurs frequently, or is accompanied by other symptoms like a fever, rash, or persistent headache, the product label indicates that use should be discontinued. These signs may indicate that the cough is due to a more serious underlying medical condition.

Q: Does taking Codepect actually cure the underlying cause of the cough?

Official product descriptions indicate that Codepect is intended for the temporary relief of cough and cold symptoms. It works by suppressing the cough reflex and thinning mucus, but it does not address or cure the underlying medical condition that is causing the cough.

Q: Are there different versions or strengths of Codepect that are officially available?

Yes, the medicine is officially available in multiple dosage forms, which may include a liquid solution, softgel capsules, or tablets. Furthermore, official product information lists different available strengths of the active ingredients within these dosage forms.

How should Codepect be stored and disposed of?

How to Store and Dispose of Codepect

Codepect (Codeine/Guaifenesin) must be stored and disposed of strictly according to official regulatory labeling to ensure product stability and prevent misuse.

Storage Requirements

The medication must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed and protected from light and excessive moisture. The product must not be frozen.

Security and Disposal

Due to the presence of Codeine, it is mandatory to store the medicine in a safe, secure place, out of the sight and reach of children and pets.

Unused or expired product should be discarded via a drug take-back program. If this option is unavailable, the drug should be mixed with an undesirable substance (e.g., used coffee grounds) and sealed in a bag for the household trash. Do not flush the medicine down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Codepect found in:

A-Z Index: